Treatment of diabetes mellitus: The future

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

For more than half a century the management of hyperglycemia in diabetes mellitus has included rigid diets and intermittent subcutaneous insulin administration. These methods have been totally unsuccessful in restoring glucose homeostasis to normal in most diabetic patients. This review focuses on techniques that offer promise as alternatives or adjuncts to the current modalities of treatment. Specific areas discussed include pancreatic transplantation, islet cell transplantation, artificial beta cell devices, and the glucagon-suppressing agent somatostatin. Although many of these show promise for the future, a cure for the metabolic abnormalities of diabetes is not imminent.

Original languageEnglish (US)
Pages (from-to)780-796
Number of pages17
JournalMetabolism
Volume28
Issue number7
DOIs
StatePublished - 1979

Fingerprint

Insulin Infusion Systems
Islets of Langerhans Transplantation
Cell Transplantation
Somatostatin
Glucagon
Islets of Langerhans
Hyperglycemia
Diabetes Mellitus
Homeostasis
Transplantation
Insulin
Diet
Glucose
Equipment and Supplies
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Treatment of diabetes mellitus : The future. / Raskin, Philip.

In: Metabolism, Vol. 28, No. 7, 1979, p. 780-796.

Research output: Contribution to journalArticle

Raskin, Philip. / Treatment of diabetes mellitus : The future. In: Metabolism. 1979 ; Vol. 28, No. 7. pp. 780-796.
@article{22726d7f95df4185856f62401c305747,
title = "Treatment of diabetes mellitus: The future",
abstract = "For more than half a century the management of hyperglycemia in diabetes mellitus has included rigid diets and intermittent subcutaneous insulin administration. These methods have been totally unsuccessful in restoring glucose homeostasis to normal in most diabetic patients. This review focuses on techniques that offer promise as alternatives or adjuncts to the current modalities of treatment. Specific areas discussed include pancreatic transplantation, islet cell transplantation, artificial beta cell devices, and the glucagon-suppressing agent somatostatin. Although many of these show promise for the future, a cure for the metabolic abnormalities of diabetes is not imminent.",
author = "Philip Raskin",
year = "1979",
doi = "10.1016/0026-0495(79)90186-0",
language = "English (US)",
volume = "28",
pages = "780--796",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "7",

}

TY - JOUR

T1 - Treatment of diabetes mellitus

T2 - The future

AU - Raskin, Philip

PY - 1979

Y1 - 1979

N2 - For more than half a century the management of hyperglycemia in diabetes mellitus has included rigid diets and intermittent subcutaneous insulin administration. These methods have been totally unsuccessful in restoring glucose homeostasis to normal in most diabetic patients. This review focuses on techniques that offer promise as alternatives or adjuncts to the current modalities of treatment. Specific areas discussed include pancreatic transplantation, islet cell transplantation, artificial beta cell devices, and the glucagon-suppressing agent somatostatin. Although many of these show promise for the future, a cure for the metabolic abnormalities of diabetes is not imminent.

AB - For more than half a century the management of hyperglycemia in diabetes mellitus has included rigid diets and intermittent subcutaneous insulin administration. These methods have been totally unsuccessful in restoring glucose homeostasis to normal in most diabetic patients. This review focuses on techniques that offer promise as alternatives or adjuncts to the current modalities of treatment. Specific areas discussed include pancreatic transplantation, islet cell transplantation, artificial beta cell devices, and the glucagon-suppressing agent somatostatin. Although many of these show promise for the future, a cure for the metabolic abnormalities of diabetes is not imminent.

UR - http://www.scopus.com/inward/record.url?scp=0018761772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018761772&partnerID=8YFLogxK

U2 - 10.1016/0026-0495(79)90186-0

DO - 10.1016/0026-0495(79)90186-0

M3 - Article

C2 - 109734

AN - SCOPUS:0018761772

VL - 28

SP - 780

EP - 796

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 7

ER -